MarketInOut Stock Screener Log In | Sign Up

Novo Nordisk A/S Series B

XETRA • Healthcare • Drug Manufacturers - General • Quote as of 10/30/2026
Novo Nordisk A/S Series B stock price and volume chart

Company Profile

IndustryDrug Manufacturers - General
SectorHealthcare
ExchangeXETRA
Market Capitalization151,198 mln
Float3,119 mln
Earnings Date11/04/2026

EPS

3.51
Solid

P / E

10.15
Fair value

Piotroski F-Score

5 / 9
Neutral

Beneish M-Score

-2.33
Borderline

Relative Strength

80 / 100
Strongly outperforming

Debt / Equity

0.63
Moderate leverage

Business Description

Founded in Denmark over a century ago, Novo Nordisk develops and sells medicines that help people manage conditions such as diabetes, obesity, and rare hormonal or blood disorders. The company offers a range of treatments alongside smart injection devices and digital tools designed to make medication easier to use. Its products are available across most major markets worldwide, from North America and Europe to Asia, Latin America, and Africa.

Key Fundamentals

EPS3.51
P/E10.15
ROE60.88
RPS9.95
ROIC21.47
ROA21.63
Interest Cover29.90
EBITDA, mln23,320
EV / EBITDA7.18
EV / EBIT8.14
Revenue, mln44,105
EV / Revenue3.80

Quote Details

Last 35.63
Change 0.84 (2.41%)
Open 34.74
Volume 110,413
Turnover 3,934,015
Average Volume 99,735

Financial Ratios

Pre-Tax Profit Margin45
Leverage Ratio2.69
Current Ratio0.87
Price / Book5.18
Price / Tangible Book11.57
Price / Cash Flow8.54
Price / Free Cash Flow15.46
Debt / Equity0.63
Price / Sales3.50
PEG Ratio0.39

Financial Strength

Altman Z-Score3.72
Piotroski F-Score 5 / 9
Beneish M-Score-2.33
Price to Intrinsic Value0.98
Price to Lynch Fair Value0.38
Price to Graham Number2.21
Shiller PE Ratio17.14

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 2.53% 84 / 100   
1 Month 6.84% 81 / 100   
2 Months -19.5% 5 / 100   
6 Months -8.55% 18 / 100   
1 Year -14.86% 13 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog